Print
Email
Print Edition StoriesThursday, December 24, 2009
Stealthy Kala Pharmaceuticals lands $2M
By Mass High Tech staff
MHT's Julie Donnelly: Pharmaceuticals find drug development partners in colleges
Funding drugs for rare diseases
MHT's Julie Donnelly: Life science startups finding investments
Kala Pharmaceuticals Inc., a biotech firm that lists MIT chemical engineering professor Bob Langer among its board of directors, has pulled in $2 million in equity financing, according to a filing with the U.S. Securities and Exchange Commission.
The stealthy company lists Robert Paull, co-founder and managing partner of New York’s Lux Capital Management, as its CEO, in addition to two directors, Langer and Justin Hanes, professor of chemical and biomolecular engineering at Johns Hopkins University.
Kala Pharmaceuticals does not have a working website yet, though the domain kalapharmaceuticals.com is registered to Lux Capital in New York. The company is using the Boston address of law firm Mintz Levin Cohn Ferris Glovsky and Popeo PC as its contact address on the regulatory filing.
Paull is the founding CEO of Cambridge-based Genocea Biosciences, a Harvard University spinout, and if also the co-founder of emerging tech research firm Lux Research. Langer has received numerous awards, including the 2006 National Medal of Science, which he won for his research on polymers in tissue regeneration and controlled medicine release. Hanes’ principal field of research is gene therapy, cancer immunotherapy and pulmonary drug delivery, according to the Johns Hopkins website.
Langer did not return a phone call as of this writing.
RSS Feeds
Comments
Please Login/Register to post comments.
No comments have been added or approved.